R
Rakesh K. Jain
Researcher at Harvard University
Publications - 1528
Citations - 198912
Rakesh K. Jain is an academic researcher from Harvard University. The author has contributed to research in topics: Angiogenesis & Cancer. The author has an hindex of 200, co-authored 1467 publications receiving 177727 citations. Previous affiliations of Rakesh K. Jain include Government Medical College, Thiruvananthapuram & University of Oslo.
Papers
More filters
Journal ArticleDOI
Discovery of novel disaccharide antibacterial agents using a combinatorial library approach.
Michael J. Sofia,Nigel M. Allanson,Nicole T. Hatzenbuhler,Rakesh K. Jain,Ramesh Kakarla,Natan A. Kogan,Rui Liang,Dashan Liu,Domingos J. Silva,Huiming Wang,David Gange,Jan A. Anderson,Anna Chen,Feng Chi,Richard G. Dulina,Buwen Huang,Muthoni G. Kamau,Chunguang Wang,Eugene R. Baizman,Arthur Branstrom,Neil Bristol,Robert D. Goldman,Kiho Han,Clifford B. Longley,Sunita Midha,Helena R. Axelrod +25 more
TL;DR: The solid-phase synthesis of a library of moenomycin disaccharide analogues and the identification of novel antibacterial agents from this library is described.
Metabolic Tumor Profiling with pH, Oxygen, and Glucose Chemosensors on a Quantum Dot Scaffold
Christopher M. Lemon,Peter N. Curtin,Rebecca C. Somers,Andrew B. Greytak,Andrew B. Greytak,Ryan M. Lanning,Rakesh K. Jain,Moungi G. Bawendi,Daniel G. Nocera +8 more
TL;DR: Optical chemosensors that feature a quantum dot and an analyte-responsive dye permit pH, oxygen, and glucose to be monitored dynamically within the tumor microenvironment by using multiphoton imaging.
Journal ArticleDOI
TGF-β blockade controls ascites by preventing abnormalization of lymphatic vessels in orthotopic human ovarian carcinoma models
TL;DR: It is reasonable to consider the use of TGF-β blockade as a palliative treatment for symptomatic ascites and prevent ‘abnormalization’ of diaphragm lymphatic vessels and improved ascites drainage.
Journal ArticleDOI
Neovascularization After Irradiation: What is the Source of Newly Formed Vessels in Recurring Tumors?
TL;DR: It is suggested that infiltrating myeloid bone marrow-derived cells promote survival of local endothelial cells during the early period after irradiation and angiogenesis during the later stage of tumor regrowth, both via paracrine mechanisms.
Journal ArticleDOI
Preclinical Efficacy of Ado-trastuzumab Emtansine in the Brain Microenvironment
Vasileios Askoxylakis,Gino B. Ferraro,David P. Kodack,Mark Badeaux,Ram C. Shankaraiah,Giorgio Seano,Jonas Kloepper,Trupti Vardam,John D. Martin,Kamila Naxerova,Divya Bezwada,Xiaolong Qi,Martin K. Selig,Elena F. Brachtel,Dan G. Duda,Peigen Huang,Dai Fukumura,Jeffrey A. Engelman,Rakesh K. Jain +18 more
TL;DR: T-DM1 can overcome resistance to trastuzumab therapy in HER2-driven or PI3K-driven breast cancer brain lesions due to the cytotoxicity of the DM1 component.